AstraZeneca PLC (AZN) Financial Statements

Executive TeamFinancials
Shareholders

AstraZeneca financial statements at a glance

AstraZeneca reported revenue of $58.74 billion for fiscal year 2025 (ended December 31, 2025), up 8.6% from fiscal year 2024. Net income was $10.23 billion, a net margin of 17.4%, and diluted earnings per share were $6.54.

At the end of fiscal year 2025 it had total assets of $114.07 billion, total liabilities of $65.36 billion and shareholders' equity of $48.67 billion, with cash and short-term investments of $5.72 billion and total debt of $29.15 billion.

Its operations brought in $14.58 billion of cash; capital spending was $5.91 billion, leaving free cash flow of $8.67 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

AZN logo

AstraZeneca PLC

AZNUnited Kingdom
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
58.74B
Prev Year: 54.07B
YoY: +8.6%
Operating Revenue
58.74B
Prev Year: 54.07B
YoY: +8.6%
Total Unusual Items Excluding Goodwill
367.00M
Prev Year: -153.00M
YoY: +339.9%
Total Unusual Items
367.00M
Prev Year: -153.00M
YoY: +339.9%
Normalized EBITDA
19.14B
Prev Year: 15.59B
YoY: +22.8%
Tax Rate for Calcs
0.18
Prev Year: 0
Tax Effect of Unusual Items
66.06M
Prev Year: -29.05M
YoY: +327.4%
Rent Expense (supplemental)
452.00M
Prev Year: 377.00M
YoY: +19.9%
Total Operating Income as Reported
13.74B
Prev Year: 10.00B
YoY: +37.4%
Noncontrolling Interests
-8.00M
Prev Year: -6.00M
YoY: -33.3%
Other Operating Expenses
134.00M
Prev Year: 121.00M
YoY: +10.7%
Selling and Marketing Expense
579.00M
Prev Year: 555.00M
YoY: +4.3%
Cost of Revenue
10.63B
Prev Year: 10.21B
YoY: +4.2%
Gross Profit
48.11B
Prev Year: 43.87B
YoY: +9.7%
Operating Expense
34.78B
Prev Year: 33.62B
YoY: +3.5%
Selling General and Administrative
20.77B
Prev Year: 20.22B
YoY: +2.7%
General and Administrative Expense
20.20B
Prev Year: 19.67B
YoY: +2.7%
Research and Development
14.23B
Prev Year: 13.58B
YoY: +4.8%
Operating Income
13.33B
Prev Year: 10.25B
YoY: +30.0%
Net Non Operating Interest Income Expense
-1.25B
Prev Year: -1.34B
YoY: +6.2%
Non-operating Interest Income
360.00M
Prev Year: 345.00M
YoY: +4.3%
Non-operating Interest Expense
1.61B
Prev Year: 1.68B
YoY: -4.0%
Special Income Charges
416.00M
Restructuring and Mergers Acquisition
-44.00M
Other Special Charges
-372.00M
Pre-tax Income
12.40B
Prev Year: 8.69B
YoY: +42.7%
Provision for Income Taxes
2.17B
Prev Year: 1.65B
YoY: +31.5%
Net Income Common Stockholders
10.22B
Prev Year: 7.04B
YoY: +45.3%
Net Income
10.22B
Prev Year: 7.04B
YoY: +45.3%
Net Income Including Non-Controlling Interests
10.23B
Prev Year: 7.04B
YoY: +45.3%
Net Income from Continuing Operations
10.23B
Prev Year: 7.04B
YoY: +45.3%
Diluted NI Available to Com Stockholders
10.22B
Prev Year: 7.04B
YoY: +45.3%
Basic EPS
6.6
Prev Year: 4.54
YoY: +45.4%
Diluted EPS
6.54
Prev Year: 4.5
YoY: +45.3%
Weighted Average Shares (basic)
1.55B
Prev Year: 1.55B
YoY: 0.0%
Weighted Average Shares (diluted)
1.56B
Prev Year: 1.56B
YoY: -0.1%
Total Expenses
45.41B
Prev Year: 43.82B
YoY: +3.6%
Net Income from Continuing and Discontinued Operation
10.22B
Prev Year: 7.04B
YoY: +45.3%
Normalized Income
9.92B
Prev Year: 7.16B
YoY: +38.6%
Interest Income
360.00M
Prev Year: 345.00M
YoY: +4.3%
Interest Expense
1.61B
Prev Year: 1.68B
YoY: -4.0%
Net Interest Income
-1.25B
Prev Year: -1.34B
YoY: +6.2%
EBIT
14.02B
Prev Year: 10.37B
YoY: +35.1%
EBITDA
19.51B
Prev Year: 15.44B
YoY: +26.4%
Reconciled Cost of Revenue
10.63B
Prev Year: 10.21B
YoY: +4.2%
Reconciled Depreciation
5.49B
Prev Year: 5.07B
YoY: +8.4%
Net Income from Continuing Operation Net Minority Interest
10.22B
Prev Year: 7.04B
YoY: +45.3%
Values in USD

AstraZeneca key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$58.7B$54.1B$45.8B$44.4B$37.4B
Gross profit$48.1B$43.9B$37.5B$32.0B$25.0B
Operating income$13.3B$10.3B$8.7B$4.5B-$139.0M
Net income$10.2B$7.0B$6.0B$3.3B$112.0M
Diluted EPS$6.54$4.50$3.81$2.11$0.08
Total assets$114.1B$104.0B$101.1B$96.5B$105.4B
Total liabilities$65.4B$63.2B$62.0B$59.4B$66.1B
Shareholders' equity$48.7B$40.8B$39.1B$37.0B$39.3B
Cash and short-term investments$5.7B$5.5B$5.9B$6.2B$6.4B
Total debt$29.1B$30.1B$28.4B$29.1B$30.7B
Operating cash flow$14.6B$11.9B$10.3B$9.8B$6.0B
Capital spending$5.9B$4.6B$3.8B$2.6B$2.2B
Free cash flow$8.7B$7.3B$6.6B$7.2B$3.8B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was AstraZeneca's revenue in fiscal year 2025?

$58.74 billion, up 8.6% from $54.07 billion in fiscal year 2024.

How much profit does AstraZeneca make?

AstraZeneca reported net income of $10.23 billion for fiscal year 2025 (17.4% of revenue); operating income was $13.33 billion.

How much cash and debt does AstraZeneca have?

At the end of fiscal year 2025: cash and short-term investments of $5.72 billion and total debt of $29.15 billion.

What is AstraZeneca's free cash flow?

$8.67 billion in fiscal year 2025 (operating cash flow of $14.58 billion minus capital spending of $5.91 billion).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube